Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment

B. Kay Young, Richard Camicioli, Linda Ganzini

    Research output: Contribution to journalReview articlepeer-review

    63 Scopus citations


    Parkinson's disease (PD) is a progressive neurological condition that causes considerable disability in the elderly. Drugs used to treat PD, such as levodopa, offer symptomatic relief but often have neuropsychiatric adverse effects, most prominently psychosis and delirium. Aged patients and those with dementia are particularly vulnerable to these adverse effects. Evaluating PD patients with drug induced neuropsychiatric adverse effects is made difficult by their complex clinical presentations. The treatment of drug-induced psychosis and delirium begins with manipulating the antiparkinsonian drug regimen, but this frequently worsens motor function. Atypical antipsychotics such as clozapine have been successfully employed to treat the psychosis without worsening the motor disability. Patient intolerance of clozapine therapy has prompted open-label studies with newer agents such as risperidone, remoxipride, zotepine, mianserin and ondansetron.

    Original languageEnglish (US)
    Pages (from-to)367-383
    Number of pages17
    JournalDrugs and Aging
    Issue number5
    StatePublished - 1997

    ASJC Scopus subject areas

    • Geriatrics and Gerontology
    • Pharmacology (medical)


    Dive into the research topics of 'Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment'. Together they form a unique fingerprint.

    Cite this